Q2 2026 revenue was 48.1 MSEK, with strong European sales and a €115M out-licensing deal for Idefirix. US launch preparations are advancing, and positive clinical data support further growth. Cash position is robust, ensuring runway into 2028.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.